Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.3880 +0.0529 (+15.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 416,038
Open 0.3700
Bid (Size) 0.3624 (60)
Ask (Size) 0.3965 (65)
Prev. Close 0.3351
Today's Range 0.3520 - 0.3900
52wk Range 0.3150 - 5.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
Exposures COVID-19
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
From Mainz BioMed NV
Via GlobeNewswire

Performance

YTD
-66.84%
-66.84%
1 Month
-49.61%
-49.61%
3 Month
-64.07%
-64.07%
6 Month
-66.26%
-66.26%
1 Year
-91.47%
-91.47%

More News

Read More
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Via Benzinga
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Via News Direct
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
Via News Direct
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
From Mainz BioMed NV
Via GlobeNewswire
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
From Mainz BioMed NV
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
From Mainz BioMed NV
Via GlobeNewswire
mRNA Is Promising A Breakthrough In Fighting Cancer
Via Benzinga
Exposures COVID-19
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Via Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Mainz Biomed Reports Full Year 2023 Financial Results
From Mainz BioMed NV
Via GlobeNewswire
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Via Benzinga
Exposures COVID-19
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
From Mainz BioMed NV
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.